Trading Business In Focus As Goldman Reports Q2
Goldman Sachs (NYSE:GS) is set to announce its Q2 2025 earnings on Wednesday, July 16, 2025. Consensus forecasts indicate that revenue is expected to rise by approximately 6% to $13.5 billion, while earnings are anticipated to be about $9.68 per share, reflecting an 11% increase compared to the previous year. While the overall economic forecast remains ambiguous due to persistent worries regarding tariffs affecting major trading partners—which may incite inflation and hinder growth—Goldman is projected to gain from robust performance in its trading division. Additionally, Goldman's asset and wealth management sector is likely to perform well, given the market's strength during Q2. The bank managed a record $3.17 trillion in assets in Q1, and this figure is expected to have increased further in Q2, supported by an approximate 10% rise in the S&P 500 index during the quarter. However, investment banking revenues at the bank are expected to stay under strain, as geopolitical tensions and tariff-induced uncertainties continue to impact mergers, acquisitions, and IPO activities.
The company possesses a current market capitalization of $223 billion. Revenue over the past twelve months reached $54 billion, with net income recorded at $15 billion. Therefore, if you are looking for potential gains with lower volatility than individual stocks, the Trefis High Quality portfolio offers an alternative, having outperformed the S&P 500 and generated returns over 91% since its inception.
View earnings reaction history of all stocks
Goldman Sachs' Historical Chances of Positive Post-Earnings Return
A few insights into one-day (1D) post-earnings returns:
Further data regarding the observed 5-Day (5D) and 21-Day (21D) returns post-earnings, along with the associated statistics, are summarized in the table below.
GS 1D, 5D, and 21D Post Earnings Return
Correlation Between 1D, 5D, and 21D Historical Returns
A relatively lower-risk strategy (although not efficient if the correlation is weak) involves examining the correlation between short-term and medium-term returns following earnings, identifying the pair with the highest correlation, and executing the suitable trade. For instance, if the correlation between 1D and 5D is the strongest, a trader could take a "long" position for the following 5 days if the 1D post-earnings return is positive. Below is some correlation data derived from 5-year and 3-year (more recent) history. Please note that the correlation between 1D and 5D refers to the relationship between 1D post-earnings returns and the subsequent 5D returns.
GS Correlation Between 1D, 5D, and 21D Historical Returns
Discover more about the Trefis RV strategy, which has outperformed its all-cap stocks benchmark (a combination of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong returns for investors. Additionally, if you're seeking potential gains with a smoother experience than an individual stock like Goldman Sachs, consider the High Quality portfolio, which has surpassed the S&P and recorded returns exceeding 91% since its inception.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback
Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year earnings forecast. Quarterly sales reached $14.05 billion, almost in line with the analysts' consensus estimate of $14.06 billion. Net sales grew 12% year over year (+11% on constant currency or cc) with core operating income up 20% to $5.93 billion (+21% on constant currency).Sales growth driven by performance from breast cancer treatment, Kisqali ($1.18 billion, +64% cc), Entresto ($2.36 billion, +22% cc), multiple sclerosis drug, Kesimpta ($1.08 billion, +33% cc), Scemblix ($298 million, +79% cc), Leqvio ($298 million, +61% cc), and Pluvicto ($454 million, +30% cc). Novartis reported adjusted earnings of $2.42 per share, beating the consensus of $2.38. The company also announced a substantial share buyback program. Novartis said it is initiating a share buyback of up $10 billion to be completed by year-end 2027. View more earnings on NVS 'Our robust balance sheet and confidence in our mid- and long-term growth enable us to initiate an up-to $10 billion share buyback as part of our commitment to balanced capital allocation,' stated CEO Vas Narasimhan in a statement on Thursday. Earlier in July, Novartis released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing giant cell arteritis (GCA). The study evaluated Cosentyx with a 26-week steroid taper and compared it to a placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically significant improvement in sustained remission at Week 52 compared to placebo. Outlook For fiscal year 2025, Novartis reaffirms that net sales will grow in the high single digits. 2025 core operating income is expected to grow in the low teens, compared to the low double digits forecasted earlier. 'We continue to assume Entresto US generic entry in mid-2025 for forecasting purposes, though the timing of generic entry is subject to ongoing IP and regulatory litigation,' Novartis said in the release. Management Update In a separate announcement, Novartis provided a key leadership update: Chief Financial Officer Harry Kirsch will retire in March 2026, concluding an impressive 22-year tenure at the company, including 12 years in the CFO role since 2013. He will be succeeded by Mukul Mehta, who currently serves as the company's head of business planning and analysis, digital finance, and tax. Price Action: NVS stock is trading lower by 1.71% to $116.35 during the premarket session at last check Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? NOVARTIS (NVS): Free Stock Analysis Report This article Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
8 minutes ago
- Business Wire
Mirion Announces Earnings Release and Conference Call Date for Second Quarter 2025
ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that it will release financial results for second quarter 2025 after market close on Thursday, July 31, 2025. Following the news release, the company will host a conference call the next day, Friday, August 1, 2025, at 10:00 am ET to discuss the results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at A telephonic replay will be available shortly after the conclusion of the call and until August 15, 2025. Participants may access the replay at 1-844-512-2921 or 1-412-317-6671 with access code 13754545. An archived replay of the call will also be available on the Investors portion of the Mirion website at About Mirion Mirion (NYSE: MIR) is a global leader in radiation safety, science and medicine, empowering innovations that deliver vital protection while harnessing the transformative potential of ionizing radiation across a diversity of end markets. The Mirion Nuclear & Safety group provides proven radiation safety technologies that operate with precision – for essential work within R&D labs, critical nuclear facilities, and on the front lines. The Mirion Medical group solutions help enhance the delivery and ensure safety in healthcare, powering the fields of Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry, and Diagnostic Imaging. Headquartered in Atlanta (GA – USA), Mirion employs approximately 2,800 people and operates in 12 countries. Learn more at
Business Wire
8 minutes ago
- Business Wire
Oklo Advances Licensing with Completion of NRC Readiness Assessment
SANTA CLARA, Calif.--(BUSINESS WIRE)--Oklo Inc. (NYSE: OKLO), an advanced nuclear technology company, has announced the successful completion of the U.S. Nuclear Regulatory Commission's (NRC's) pre-application readiness assessment for Phase 1 of the combined license application (COLA) for Oklo's first commercial Aurora powerhouse at Idaho National Laboratory (INL). The NRC's observations affirmed Oklo's readiness to move forward, with no significant gaps identified that would hinder acceptance of the application. Observations were also provided that will help Oklo finalize the application to support an efficient and effective review process. 'We view this assessment as a productive engagement tool that moves our licensing and permitting work forward,' said Jacob DeWitte, Co-Founder and CEO of Oklo. 'Our team has worked closely with the NRC to build a clear, efficient licensing pathway, and this is a good signal that we are on track.' Oklo has proactively engaged with the NRC since 2016 and has completed a broad range of pre-application activities, including securing an approved Quality Assurance Program Description and advancing critical licensing elements such as safety analysis, component classification, and operational protocols. The completion of this assessment reflects both Oklo's innovative approach to licensing and the NRC's broader commitment—reinforced by the ADVANCE Act and recent Executive Orders—to modernize regulatory processes and enable the timely deployment of advanced nuclear technologies. Notably, the NRC's move to support standardized environmental review templates for reactor and site characteristics marks a meaningful step toward repeatable, accelerated licensing for advanced reactors. Oklo plans to submit the first phase of the Aurora-INL COLA this year. Oklo's licensing strategy supports the efficient and repeatable deployment of its Aurora powerhouses, enabling future follow-on applications to serve its growing pipeline of commercial and Federal customers. About Oklo Inc.: Oklo Inc. is developing fast fission power plants to deliver clean, reliable, and affordable energy at scale; establishing a domestic supply chain for critical radioisotopes; and advancing nuclear fuel recycling to convert nuclear waste into clean energy. Oklo was the first to receive a site use permit from the U.S. Department of Energy for a commercial advanced fission plant, was awarded fuel from Idaho National Laboratory, and submitted the first custom combined license application for an advanced reactor to the U.S. Nuclear Regulatory Commission. Oklo is also developing advanced fuel recycling technologies in collaboration with the U.S. Department of Energy and National Laboratories. Forward-Looking Statements This press release includes statements that express Oklo's opinions, expectations, objectives, beliefs, plans, intentions, strategies, assumptions, forecasts or projections regarding future events or future results and therefore are, or may be deemed to be, 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'would' or, in each case, their negative or other variations or comparable terminology, and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this press release and include statements regarding our intentions, beliefs or current expectations concerning, among other things, the benefits of the DOE's Voucher Program, results of operations, financial condition, liquidity, prospects, growth, strategies and the markets in which Oklo operates. Such forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. As a result of a number of known and unknown risks and uncertainties, the actual results or performance of Oklo may be materially different from those expressed or implied by these forward-looking statements. The following important risk factors could affect Oklo's future results and cause those results or other outcomes to differ materially from those expressed or implied in the forward-looking statements: risks related to the deployment of Oklo's powerhouses; the risk that Oklo is pursuing an emerging market, with no commercial project operating, regulatory uncertainties; the potential need for financing to construct plants, market, financial, political and legal conditions; the effects of competition; the risk that the DOE's Voucher Program fails to produce the expected benefits; changes in applicable laws or regulations; and the outcome of any government and regulatory proceedings and investigations and inquiries. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties of the other documents filed by Oklo from time to time with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release and in any document incorporated by reference are based on current expectations and beliefs concerning future developments and their potential effects on Oklo. There can be no assurance that future developments affecting Oklo will be those that Oklo has anticipated. Oklo undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
